HIV and cardiovascular disease

The event of persistent disease complications in controlled HIV disease has changed the landscape of HIV clinical care. HIV infection provides an opportunity to advance cardiovascular disease, which is thought to be caused by a complex interaction of modifying factors. While common components of cardiovascular risk likely play a role, he later demonstrates that HIV-related disruption and safe sanctions are the fundamental transition between cardiovascular risks.

It is questionable whether the established prevention interventions for the general masses are relevant to HIV-infected patients, and decoding the dumb data into HIV-specific clinical mediation conversations is a fundamental requirement. Established strategies to avoid cardiovascular disease in HIV-infected persons require a multidisciplinary approach and speak to the opportunity to exert a large open influence on prosperity in at-risk populations


    Related Conference of HIV and cardiovascular disease

    November 28-29, 2024

    38th International Conference on Immunology

    Aix-en-Provence, France
    December 12-13, 2024

    5th International Conference on Immunology And Immunotherapy

    Zurich, Switzerland
    June 16-17, 2025

    19th International Conference on European Immunology

    Frankfurt, Germany

    HIV and cardiovascular disease Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in